160 related articles for article (PubMed ID: 38261737)
1. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
[TBL] [Abstract][Full Text] [Related]
2. The circadian rhythm key gene
Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
[TBL] [Abstract][Full Text] [Related]
3. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
4. Signal sequence receptor subunit 3: A novel indicator of immunosuppressive tumor microenvironment and clinical benefits from immunotherapy.
Hu Q; Wu G; Ma H; Zhang J; Yang Z
Cell Signal; 2023 Nov; 111():110871. PubMed ID: 37652395
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
6.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
7. A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker.
Huang Y; Zhou X; Li X; Huang D; Fang Z; Ding R
Oncol Res; 2023; 31(2):193-205. PubMed ID: 37304239
[TBL] [Abstract][Full Text] [Related]
8. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
9.
Zhang W; Liao Y; Liu C; Liu L; Zhou X
Dis Markers; 2023; 2023():6729717. PubMed ID: 36845017
[TBL] [Abstract][Full Text] [Related]
10. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.
Zheng H; Wang M; Zhang S; Hu D; Yang Q; Chen M; Zhang X; Zhang Y; Dai J; Liou YC
Int J Biol Sci; 2023; 19(14):4689-4708. PubMed ID: 37781040
[TBL] [Abstract][Full Text] [Related]
12. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
13. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
[TBL] [Abstract][Full Text] [Related]
14. Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response.
Li Z; Li Y; Tian Y; Li N; Shen L; Zhao Y
Front Immunol; 2023; 14():1170539. PubMed ID: 37275863
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
16. The Pan-Cancer Landscape of Crosstalk Between TRP Family and Tumour Microenvironment Relevant to Prognosis and Immunotherapy Response.
Wu G; He M; Yin X; Wang W; Zhou J; Ren K; Chen X; Xue Q
Front Immunol; 2022; 13():837665. PubMed ID: 35493463
[TBL] [Abstract][Full Text] [Related]
17. The role of Angiogenesis and remodeling (AR) associated signature for predicting prognosis and clinical outcome of immunotherapy in pan-cancer.
Sun X; Zhang Z; Wang Z; Xie R; Yi C; Liu H; Chi X; Li T; Liu H; Han Y; Pang X; Cui Y; Liu Z
Front Immunol; 2022; 13():1033967. PubMed ID: 36479101
[TBL] [Abstract][Full Text] [Related]
18. Pan-cancer analysis of TASL: a novel immune infiltration-related biomarker for tumor prognosis and immunotherapy response prediction.
Li H; Sun X; Zhao Y; Zhang C; Jiang K; Ren J; Xing L; He M
BMC Cancer; 2023 Jun; 23(1):528. PubMed ID: 37296415
[TBL] [Abstract][Full Text] [Related]
19. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers.
Gao X; Bu H; Gao X; Wang Y; Wang L; Zhang Z
FASEB J; 2023 Oct; 37(10):e23159. PubMed ID: 37650687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
